| |
Wilmington Pathology Associates, P.A. Enhances Molecular Diagnostic Capabilities
Wilmington, North Carolina: January 10, 2006– Wilmington Pathology Associates, P.A. announces the implementation of the new molecular diagnostic testing for Human Papillomavirus (HPV) infections of the female genital tract. Human Papillomavirus is the cause of cervical cancer, a disease affecting approximately 13,000 women annually in the U.S. Wilmington Pathology has selected and validated a polymerase chain reaction (PCR) based methodology for HPV testing for the determination of the presence of HPV and restriction fragment length polymorphism (RFLP) analysis for HPV genotype identification. When combined with clinical information and cytologic diagnoses, this new method allows WPA’s pathologists to more accurately diagnose HPV-related changes and allows a more specific assessment of patient risk for development of cervical cancer.
Using Access Genetics’ Web-Enabled DNA Testing Model, WPA is able to use existing staff and technical capabilities to perform front-end DNA extraction and gene chemistry from a variety of specimen types. A digital image of each test sample is then captured and transmitted to Access Genetics via a secure web portal, where American College of Medical Geneticists certified pathologists perform analysis and interpretation. A comprehensive test result and risk assessment is delivered back to Wilmington Pathology’s laboratory within hours.
“We are excited to be offering this advancement in patient care,” said Dr. Christopher McKinney of Wilmington Pathology. “By utilizing our expertise in gynecologic pathology at Wilmington Pathology Associates along with the experience of Access Genetics staff in molecular detection of HPV types, we can provide a more specific and accurate diagnosis for our patients with faster turn-around time.”
Back
|
